Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | CALML3 | P27482 | 7/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SDHA | P31040 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5001514 | 1.00 | F10 (0.42) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL14029054 | 1.00 | F10 (0.42) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL5004965 | 0.85 | F10 (0.45) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL14029041 | 0.85 | F10 (0.45) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL5004964 | 0.85 | F10 (0.45) | F10MAOACALML3GRM2MAOB | |
| SCHEMBL5114214 | 0.84 | MAOA (0.55) | F10MAOACALML3MAOBLMNA | |
| SCHEMBL5114206 | 0.84 | MAOA (0.55) | F10MAOACALML3MAOBLMNA | |
| SCHEMBL5001360 | 0.83 | F10 (0.43) | F10MAOACALML3GRM2 | |
| SCHEMBL5001354 | 0.83 | F10 (0.43) | F10MAOACALML3GRM2 | |
| SCHEMBL5503449 | 0.83 | MAOA (0.58) | F10MAOACALML3MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | PFIZER INC | 2008-10-23 | — | — | US | disclosed |
| US-7435751-B2 | 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents | JOSYULA VARA PRASAD VENKATA NAGENDRA | 2008-10-14 | — | — | US | disclosed |
| US-20060229349-A1 | 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229349-A1 | 7-Fluoro-1,3-dihydro-indol-2-one oxazolidinones as antibacterial agents | OXA1L, MRPL21, FOXM1 | F10 2213/4885MAOA 1101/4885CALML3 1349/4885 |
| US-20080262056-A1 | Oxindole Oxazolidinones as Antibacterial Agents | OXA1L, OXSR1, OXER1 | F10 784/4885MAOA 447/4885CALML3 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.